Publications for Per Rosenberg
Co-author map based on ISI articles 2007-

Journal Articles

Kristina Lindemann, Susanne Malander, Rene D. Christensen, Mansoor R. Mirza, Gunnar B. Kristensen, Elisabeth Aavall-Lundqvist, Ignace Vergote, Per Rosenberg, Karin Boman and Britta Nordstrom
  Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
  BMC Cancer, 2014, 14(68), .
   Fulltext  PDF  

Anne von Heideman, Bengt Tholander, Birgitta Grundmark, Stefan Cajander, Eva Gerdin, Leif Holm, Agneta Axelsson, Per Rosenberg, Haile Mahteme, Erika Daniel, Rolf Larsson and Peter Nygren
  Chemotherapeutic drug sensitivity of primary cultures of epithelial ovarian cancer cells from patients in relation to tumour characteristics and therapeutic outcome
  Acta Oncologica, 2014, 53(2), 242-250.

Henrik Green, Peter Söderkvist, Per Rosenberg, Rajaa A Mirghani, Per Rymark, Elisabeth Avall Lundqvist and Curt Peterson
  Pharmacogenetic Studies of Paclitaxel in the Treatment of Ovarian Cancer
  Basic and clinical pharmacology and toxicology, 2009, 104(2), 130-137.
   Fulltext  PDF  
 Web of Science® Times Cited: 43

B. Sorbe, H. Andersson, K. Boman, Per Rosenberg and M. Kalling
  Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel - Long-term follow-up
  International Journal of Gynecological Cancer, 2008, 18(4), 803-808.
 Web of Science® Times Cited: 29

Henrik Green, Peter Söderkvist, Per Rosenberg, Grörgy Horvath and Curt Peterson
  ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel
  Journal of Pharmaceutical Sciences, 2008, 97(6), 2045-2048.
   Fulltext  PDF  
 Web of Science® Times Cited: 28

Henrik Green, Peter Söderkvist, Per Rosenberg, Rajaa A. Mirghani, Per Rymark, Elisabeth Åvall-Lundqvist and Curt Peterson
  Pharmacogenetics of Paclitaxel in the Treatment of Ovarian Cancer – a Pilot Study in Preparation of Individualized Chemotherapy
  Clinical Cancer Research, 2007, , .

Henrik Green, Peter Söderkvist, Per Rosenberg, Horvath György and Curt Peterson
  Letters to the Editor: ABCB1 2677>T/A Genotype and paclitaxel pharmacogenetics in ovarian cancer - Response
  Clinical Cancer Research, 2006, 12(13), 4127-4129.
 Web of Science® Times Cited: 2

Henrik Green, Per Rosenberg, Peter Söderkvist, György Horvath and Curt Peterson
  β-tubulin mutations in ovarian cancer using single strand conformation analysis – risk of false positive results from paraffin embedded tissues
  Cancer Letters, 2006, 236(1), 148-154.
   Fulltext  PDF  
 Web of Science® Times Cited: 5

Henrik Green, Peter Söderkvist, Per Rosenberg, György Horvath and Curt Peterson
  mdr-1 single nucleotide polymorphisms in ovarian cancer tissue – G2677T/A correlates with response to paclitaxel chemotherapy
  Clinical Cancer Research, 2006, 12(3 pt 1), 854-859.
   Fulltext  PDF  
 Web of Science® Times Cited: 93

Ph.D. Theses

Henrik Green
  Pharmacogenetic Studies of Paclitaxel in Ovarian Cancer: focus on interindividual differences in pharmacodynamics and pharmacokinetics
  2007.


  Fulltext PDF